MOESM1 of Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema

Authors
Publication date
Publisher
Doi

    Abstract

    Additional file 1. Transition probabilities

      Similar works

      Full text

      thumbnail-image

      Available Versions

      FigShare

      redirect
      oaioai:figshare.com:article/43221...
      Last time updated on 12/02/2018

      Springer - Publisher Connector

      redirect
      Last time updated on 05/06/2019